Table 3 Clinical and vaccination data from IPD patients, <5 years of age in NSW, from whom IPD serogroup 19 isolates were isolated.

From: Genome-wide analysis of Streptococcus pneumoniae serogroup 19 in the decade after the introduction of pneumococcal conjugate vaccines in Australia

Demographic & core clinical data

 

2004

2008

2014

Total cases

 

n = 41

n = 60

n = 23

Median age, years (range)

 

1.45 (0.04–4.94)a

1.76 (0.0–4.73)

1.9 (0.0–5)

Specimen type

Bloodb

40 (98%)

59 (98%)

21 (91.3%)

Joint fluid

1(2%)

1 (2%)

CSF

2 (8.7%)

Clinical presentation

Bacteremia

22 (54%)

31 (51.5%)

11 (47.8)

Pneumonia

11 (27%)

25 (41.5%)

9 (39.1)

Septic arthritis

1 (2%)

1 (2%)

Meningitis

2 (8.7)

Unknown

7 (17%)

3 (5%)

1 (4.3)

Vaccination History

Full

1 (2%)

50 (82%)

15 (65%)

Partial

2 (5%)

6 (10%)

5 (22%)

None

31 (76%)

1 (2%)

2 (9%)

Unknown

7 (17%)

2 (3%)

1 (4%)

PCV-7 history

3 doses

1 (2.4%)

50 (83%)

5 (23%)

2 doses

6 (10%)

1 (4%)

1 dose

1 (2.4%)

1 (2%)

No PCV-7

29 (70.8%)

2 (3%)

16 (70%)

Unknown

9 (22%)

1 (2%)

1 (4%)

PCV-13 history

3 doses

10 (44%)

2 doses

4 (17%)

1 dose

1 (4%)

No PCV13

7 (30%)

Unknown

  

1 (4%)

PPV-23 history

1 dose

1 (2.4%)

Immune status

Compromised

3 (7%)

1 (2%)

2 (9%)

Competent

32 (78%)

59 (98%)

20 (87%)

Unknown

6 (15%)

1 (4%)

Indigenous statusc

Non-indigenous

98%

95%

21 (91%)

Indigenous

2%

5%

2 (9%)

  1. Notes:
  2. aAge unknown for 3 IPD cases in 2004.
  3. bClinical presentation of bacteremia includes an unknown number of cases of meningitis (lumbar puncture often performed after antibiotic therapy commenced).
  4. cAggregated percentage of IPD cases in Indigenous and non-indigenous populations where included in study years 2004 and 2008. In 2014, notified cases of IPD in Indigenous.
  5. dAbbreviations: PCV-7; −13-7 or 13-valent pneumococcal conjugate vaccine; PPV-23-23-valent pneumococcal polysaccharide vaccine. and non-indigenous children is reported.